Monitor the Special Meeting vote outcome on December 9, 2026; if approved, the board has discretion to implement the reverse split at any time before December 31, 2028, with the immediate catalyst being the January 13, 2027 Nasdaq compliance deadline. Failure to regain compliance could lead to delisting.
Price Chart
Executive Summary
20/20 Biolabs, Inc. is holding a Special Meeting on December 9, 2026 to seek stockholder approval for a reverse stock split (ratio 1-for-2 to 1-for-250) to regain compliance with Nasdaq's $1.00 minimum bid price rule, after receiving a non-compliance notice on July 17, 2026. The filing is a routine governance proxy with no executive compensation, shareholder proposals, or director election matters, and the outcome is critical to maintaining the company's Nasdaq listing.
Key Facts
- Special Meeting on December 9, 2026 to vote on authorizing reverse stock split at ratio of not less than 1-for-2 and not more than 1-for-250, effective any time before December 31, 2028
- Company received Nasdaq non-compliance notice on July 17, 2026 for failing to meet $1.00 closing bid price requirement for 30 consecutive business days (June 3 to July 16, 2026)
- 180-day compliance period granted until January 13, 2027; a second 180-day period may be available if other listing standards are met
- 13,367,204 shares of common stock outstanding as of Record Date (October 20, 2026)
- Streeterville Capital, LLC beneficially owns 3,627,627 shares (9.99%) via warrants, with a 9.99% beneficial ownership limitation
- CEO Jonathan Cohen beneficially owns 1,896,096 shares (13.64%); all executive officers and directors as a group own 3,821,722 shares (27.66%)
- No executive compensation details, say-on-pay votes, director elections, shareholder proposals, or related party transactions are included in this special meeting proxy
Financial Impact
Reverse stock split would reduce outstanding shares from 13,367,204 to between 6,683,602 (1-for-2) and 53,468 (1-for-250); no financial figures provided beyond share counts
Risk Factors
- Reverse stock split may not achieve sustained compliance with Nasdaq's bid price rule
- Reduced share count could impair liquidity, especially for larger block trades
- If reverse split is not approved or fails to cure the bid price deficiency, Nasdaq may delist the common stock
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001213900-26-111346 |
| Document: 0001213900-26-111346-index-headers.html | 0001213900-26-111346 |
| Document: 0001213900-26-111346-index.html | 0001213900-26-111346 |
| Document: 0001213900-26-111346.txt | 0001213900-26-111346 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEFA14A | $0.2507 | awaiting T+5 | — | $0.2325 (−7.26%) |
Oct 21, 2026 5d ago | DEF 14A | $0.2507 | awaiting T+5 | — | $0.2325 (−7.26%) |
Aug 17, 2026 10w ago | 8-K | $0.5200 $0.5282 | ▲ +1.58% | ▲ +1.78% | $0.2325 (−55.29%) |
Aug 17, 2026 10w ago | Press Release | $0.5503 $0.5182 | ▼ −5.83% | ▼ −4.64% | $0.2325 (−57.75%) |
Aug 5, 2026 11w ago | 8-K | $0.4413 $0.4610 | ▲ +4.46% | ▲ +4.11% | $0.2325 (−47.31%) |
Jul 1, 2026 16w ago | 8-K | $0.6095 $0.5851 | ▼ −4.00% | ▼ −4.26% | $0.2325 (−61.85%) |
Jun 23, 2026 17w ago | DEFA14A | $0.5669 $0.6095 | ▼ −7.51% | ▼ −5.81% | $0.2325 (+58.99%) |
May 26, 2026 21w ago | 8-K | $0.9700 $0.8400 | ▼ −13.40% | ▼ −13.87% | $0.2325 (−76.03%) |
May 20, 2026 22w ago | 8-K | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2325 (+80.79%) |
May 20, 2026 22w ago | Press Release | $1.21 $0.9500 | ▲ +21.49% | ▲ +23.09% | $0.2325 (+80.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers